Thrombotic thrombocytopenic purpura screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Thrombotic thrombocytopenic purpura}} | ||
{{CMG}}; {{AE}} {{S.G.}} | {{CMG}}; {{AE}} {{S.G.}} | ||
Latest revision as of 17:08, 25 February 2019
|
Thrombotic thrombocytopenic purpura Microchapters |
|
Differentiating Thrombotic thrombocytopenic purpura from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Thrombotic thrombocytopenic purpura screening On the Web |
|
American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura screening |
|
Directions to Hospitals Treating Thrombotic thrombocytopenic purpura |
|
Risk calculators and risk factors for Thrombotic thrombocytopenic purpura screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There is no insufficient evidence to recommend routine screening for TTP.
Screening
- There is no insufficient evidence to recommend routine screening for TTP.[1]
- First test to be screening for ADAMTS13 activity. ADAMTS13 activity < 10%, TTP diagnosis is confirmed.
- In sever deficiency of ADAMTS13 second screening is detection of anti-ADAMTS13 IgG
- Gene sequencing of ADAMTS13 is a third test is used.
References
- ↑ Joly, Bérangère S.; Coppo, Paul; Veyradier, Agnès (2017). "Thrombotic thrombocytopenic purpura". Blood. 129 (21): 2836–2846. doi:10.1182/blood-2016-10-709857. ISSN 0006-4971.